Insider Chart Past 6 Months
Technical Chart
Filings by transaction date
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Sullivan John JamesOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-450Price:--
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Sakys JohnOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-2,500Price:--
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Owens Gary MOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionsNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-5,000Price:--
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Archbold Brian DavidOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-420Price:--
-
Feb 16, 2024 (filed on Feb 16, 2024)Insider Name:Capone Mark ChristopherOwnership Type:Direct OwnershipSecurities:MLABNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Feb 15, 2024 (filed on Feb 16, 2024)Insider Name:Capone Mark ChristopherOwnership Type:Direct OwnershipSecurities:Restricted Stock Units -1Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:724Price:--
-
Jan 08, 2024 (filed on Mar 26, 2024)Insider Name:Archbold Brian DavidOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-290Price:--
-
Dec 15, 2023 (filed on Dec 19, 2023)Insider Name:Archbold Brian DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,500Price:$112.36
-
Nov 09, 2023 (filed on Nov 14, 2023)Insider Name:Sullivan John JamesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-2,000Price:--
-
Nov 09, 2023 (filed on Nov 14, 2023)Insider Name:Sullivan John JamesOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:200Price:--
Filings by filing date
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Sullivan John JamesOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-450Price:--
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Sakys JohnOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-2,500Price:--
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Owens Gary MOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionsNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-5,000Price:--
-
Apr 02, 2024 (filed on Apr 03, 2024)Insider Name:Archbold Brian DavidOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-420Price:--
-
Jan 08, 2024 (filed on Mar 26, 2024)Insider Name:Archbold Brian DavidOwnership Type:Direct OwnershipSecurities:Non Qualified Stock OptionNature of Transaction:E - Expiration of short derivative# or value acquired/disposed of:-290Price:--
-
Feb 15, 2024 (filed on Feb 16, 2024)Insider Name:Capone Mark ChristopherOwnership Type:Direct OwnershipSecurities:Restricted Stock Units -1Nature of Transaction:A - Grant, award or other under Rule 16b-3(d)# or value acquired/disposed of:724Price:--
-
Feb 16, 2024 (filed on Feb 16, 2024)Insider Name:Capone Mark ChristopherOwnership Type:Direct OwnershipSecurities:MLABNature of Transaction:Form 3 : Initial Statement of Beneficial Ownership of Securities# or value acquired/disposed of:--Price:--
-
Dec 15, 2023 (filed on Dec 19, 2023)Insider Name:Archbold Brian DavidOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:S - Open market or private sale# or value acquired/disposed of:-1,500Price:$112.36
-
Nov 09, 2023 (filed on Nov 14, 2023)Insider Name:Sullivan John JamesOwnership Type:Direct OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:-2,000Price:--
-
Nov 09, 2023 (filed on Nov 14, 2023)Insider Name:Sullivan John JamesOwnership Type:Indirect OwnershipSecurities:Common StockNature of Transaction:G - Gift# or value acquired/disposed of:200Price:--
News
Biz Brief
Sector: Healthcare | Industry: Medical Equipment, Supplies & Distribution |
See Regulatory Filings on SEC |
Company Contact | |
Address: | 12100 W 6th Ave LAKEWOOD 80228-1252 |
Tel: | N/A |
Website: | https://mesalabs.com |
IR: | See website |
Key People | ||
Gary M. Owens President, Chief Executive Officer, Director | John V. Sakys Chief Financial Officer, Vice President | Brian Archbold Senior Vice President - Continuous Improvement |
Business Overview |
Mesa Laboratories, Inc. is a multinational manufacturer, developer, and seller of life sciences tools and critical quality control solutions. Its segments include Clinical Genomics, Sterilization and Disinfection Control, Biopharmaceutical Development, and Calibration Solutions. Its Clinical Genomics segment develops, manufactures, and sells throughput genetic analysis tools used by labs to perform clinical genomic testing in several therapeutic areas. Its Sterilization and Disinfection Control segment manufactures and sells biological, chemical, and cleaning indicators used to assess the effectiveness of sterilization and disinfection processes. Biopharmaceutical Development segment develops, manufactures, and sells automated systems for protein analysis (immunoassays) and peptide synthesis solutions. Its Calibration Solutions segment develops, manufactures, and sells quality control products used to measure or calibrate temperature, pressure, pH, humidity, and other such parameters. |
Financial Overview |
For the nine months ended 31 December 2023, Mesa Laboratories Inc revenues decreased 4% to $157.3M. Net income increased 6% to $337K. Revenues reflect Clinical Genomics segment decrease of 15% to $41.5M, Biopharmaceutical Development segment decrease of 18% to $28.5M, United States segment decrease of 11% to $79.2M, China segment decrease of less than 1% to $18.6M. |
Employees: | 698 as of Mar 31, 2023 |
Reporting Currency: | U.S. Dollars |
Enterprise value: | $753.86M as of Dec 31, 2023 |
Annual revenue (TTM): | $212.87M as of Dec 31, 2023 |
EBITDA (TTM): | $35.69M as of Dec 31, 2023 |
Net annual income (TTM): | $0.95M as of Dec 31, 2023 |
Free cash flow (TTM): | $37.27M as of Dec 31, 2023 |
Net Debt Last Fiscal Year: | $204.74M as of Dec 31, 2023 |
Shares outstanding: | 5,394,051 as of Jan 29, 2024 |
Index Membership: | S&P 600 Small Cap |
TTM: Trailing Twelve Months EBITDA: Earnings Before Interest, Taxes, Depreciation, & Amortization |